Adverse effects for the infant or mother · increasing breast milk production in mothers of non‐hospitalised term infants
1 finding from 1 review
Participant's global assessment of improvement Non‐standardised scale5 · Mild, moderate and severe acne vulgaris
1 finding from 1 review
Lesion count · Mild, moderate and severe acne vulgaris
1 finding from 1 review
Investigator‐assessed severe adverse effects Blistering or scarring · Mild, moderate and severe acne vulgaris
1 finding from 1 review
1‐year mortality · previously treated patients with mRCC
Targeted immunotherapy alone probably leads to lower 1‐year mortality compared with standard targeted therapies (moderate certainty).
1 finding from 1 review
Quality of life: improved to an important degree · previously treated patients with mRCC
Targeted immunotherapy alone probably leads to higher quality of life: Clinically relevant improvement in FKSI‐DRS compared with standard targeted therapies (moderate certainty).
2 findings from 1 review
Adverse events (grade ≥ 3) · previously treated patients with mRCC
Targeted immunotherapy alone probably leads to lower adverse events (grade ≥ 3) compared with standard targeted therapies (moderate certainty).
1 finding from 1 review
Breast pain · women with breast engorgement during lactation
1 finding from 1 review
Breast induration/hardness · women with breast engorgement during lactation
1 finding from 1 review
Breast swelling · women with breast engorgement during lactation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Breast engorgement · women with breast engorgement during lactation
1 finding from 1 review
Maternal opinion of treatment · women with breast engorgement during lactation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cessation of breastfeeding, · women with breast engorgement during lactation
1 finding from 1 review
Number of women with adverse events · women with breast engorgement during lactation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
1‐Year survival rate · non‐small cell lung cancer in the elderly population
Non‐platinum therapies probably leads to lower 1‐Year survival rate compared with platinum combination (moderate certainty).
1 finding from 1 review
Progression‐free survival · non‐small cell lung cancer in the elderly population
Non‐platinum therapies may leads to lower progression‐free survival compared with platinum combination (low certainty).
1 finding from 1 review
Objective response rate · non‐small cell lung cancer in the elderly population
Non‐platinum therapies probably leads to higher objective response rate (ORR) compared with platinum combination (moderate certainty).
1 finding from 1 review
QoL · non‐small cell lung cancer in the elderly population
1 finding from 1 review
Overall survival · non‐small cell lung cancer in the elderly population
Non‐platinum therapies probably leads to lower overall survival compared with platinum combination (moderate certainty).
1 finding from 1 review
BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review